Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
The user experienced gradual hair thinning since 2021 and tried various treatments including topical minoxidil, rosemary oil, oral finasteride, oral minoxidil, RU58841, and oral dutasteride. They are considering switching to daily finasteride and adding topical dutasteride, tretinoin, and microneedling due to side effects from oral dutasteride.
The user experienced intensified hair thinning after 10 years on finasteride and saw little improvement after switching to oral minoxidil and dutasteride for 8 months. Suggestions included continuing dutasteride for another 6-8 months, considering additional treatments like topical finasteride, and evaluating nutrition and other potential causes of hair loss.
A 26-year-old male experienced hair thinning since age 18 and tried various treatments, including topical minoxidil, oral finasteride, and a hair transplant. He is currently using topical finasteride, minoxidil, tretinoin, hydrocortisone, and oral dutasteride, and is satisfied with the results 6.5 months post-transplant.
Using a combination of finasteride, minoxidil, dermarolling, and RU58841 to treat hair loss. Participants discussed the time commitment required for treatment and the effectiveness of different dosages.
A 40-year-old started using oral finasteride and topical minoxidil for hair loss, seeing improvements after 5 weeks. They plan to try a dermastamp for better results, as they experienced scalp irritation with dermarolling.
Post Finasteride Syndrome (PFS) is debated, with some users reporting severe side effects from finasteride, while others believe these effects are rare or psychosomatic. Treatments discussed include finasteride, minoxidil, and RU58841.
A user shared their 2-month progress using 1mg finasteride daily, 5% minoxidil with 0.1% finasteride topically twice a day, and Vitamin D3 weekly. They experienced initial side effects like weaker erections and mood swings, which resolved after one month.
User is experiencing hair thinning and sebum overproduction after starting finasteride and a hair growth supplement containing biotin, iron, zinc, and calcium. They suspect the finasteride might be fake but have noticed a side effect of watery semen.
A 19-year-old male experiencing diffuse hair thinning has been using oral minoxidil and finasteride for 6 months with no improvement. Suggestions include continuing the treatment, checking for underlying conditions, and considering nutritional or hormonal causes.
New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.
The user experienced side effects from using 1% finasteride and 2% minoxidil, including dermatitis, erectile dysfunction, and heart palpitations. They switched to using 2000mg pumpkin seed oil, saw palmetto capsules, and applying pumpkin seed oil and rosemary oil twice a week, seeking feedback on results.
The user experienced no improvement in hair loss after using a dermatologist's minoxidil 10% and finasteride 0.1% solution, clotrimazole, daily dermarolling, and multivitamins. They plan to switch to oral finasteride and reduce dermarolling to once a week.
A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.
A 24-year-old experiencing severe hair thinning has been using minoxidil for 2 years but is still shedding hair. A doctor recommended plasma treatment over a DHT blocker for better and healthier results.
A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.
The user experienced hair thinning on TRT and considered various treatments suggested by an online clinic, including GHK-Cu Scalp Serum and Minoxidil blends. The consensus is that only finasteride or dutasteride effectively stop hair loss, while Minoxidil can thicken hair.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
Topical finasteride with minoxidil effectively stabilized and thickened hair but caused side effects like brain fog, reduced libido, and emotional flattening, leading to discontinuation. The user switched to a new regimen including minoxidil, KX-826, and other treatments, noting improvements in libido and vivid dreams after stopping finasteride.
The conversation is about someone's progress with hair loss treatment using a combination of topical finasteride and minoxidil, and dermastamping once a week. They are considering increasing the dermastamp needle size from 1.25mm to 1.5mm.
The user experienced heart palpitations after increasing their oral minoxidil dosage and starting a new topical minoxidil formulation. They wish to stop oral minoxidil for heart health and continue with topical minoxidil.
The user's hair thinning and shedding were due to Telogen effluvium caused by COVID-19, not the ineffectiveness of Finasteride. The shedding eventually slowed, and hair growth resumed, but the user was advised to consider additional treatments like Minoxidil or microneedling if needed.
A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.